Drug intelligence / Profile preview

camrelizumab + apatinib + nab-paclitaxel + epirubicin + cyclophosphamide

Development stage: Unknown
Lead developer: West China Hospital of Sichuan University
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

This combination regimen is a neoadjuvant therapy being investigated for the treatment of stage II-III triple-negative breast cancer (TNBC). It is the subject of a Phase II clinical trial (NCT05447702) sponsored by West China Hospital. The regimen combines the anti-PD-1 monoclonal antibody camrelizumab with the small molecule VEGFR-2 tyrosine kinase inhibitor apatinib and a standard chemotherapy backbone consisting of nab-paclitaxel followed by epirubicin and cyclophosphamide. The rationale for this combination is to synergize the immune-potentiating effects of PD-1 blockade with the anti-angiogenic and tumor microenvironment-modulating effects of VEGFR inhibition, alongside the direct cytotoxic effects of chemotherapy, to improve pathological complete response rates in patients with aggressive TNBC.

Other names: Camrelizumab Plus Apatinib and ChemotherapyApatinib-West China Hospital-TNBC regimen

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)TOP2A (DNA topoisomerase II)DNASRC (Proto-oncogene tyrosine-protein kinase Src)TUBB (Tubulin (alpha and beta subunits))KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on camrelizumab + apatinib + nab-paclitaxel + epirubicin + cyclophosphamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camrelizumab + apatinib + nab-paclitaxel + epirubicin + cyclophosphamide.

Explore the full profile